P1.21-11 Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%.
| Autor: | Suga, J., Thomas, S., Achacoso, N., Jiang, C., Chung, E., Solorzano-Pinto, A., Tse, P., Bulen, B.J., Khazanov, N.A., Lamb, L.E., Hovelson, D.H., Kwiatkowski, K., Johnson, D.B., Rhodes, D.R., Tomlins, S.A., Habel, L.A. |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2023 Supplement, Vol. 18 Issue 11, pS238-S239, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|